Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Piracetam,Inapplicable
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : UCB Pharma S.A
Deal Size : Undisclosed
Deal Type : Partnership
M8 Pharmaceuticals and UCB Partner for Central Nervous System and Respiratory Portfolio in Mexico
Details : According to IQVIA, the portfolio has annual sales of approximately $26 million dollars and includes drugs such as: ATARAX®, NOOTROPIL®, XUZAL®, and VIRLIX®.
Product Name : Nootropil
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 22, 2021
Lead Product(s) : Piracetam,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : UCB Pharma S.A
Deal Size : Undisclosed
Deal Type : Partnership
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2013
Lead Product(s) : Levocarnitine,Piracetam
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 09, 2012
Lead Product(s) : Levocarnitine,Piracetam
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable